# CeeD (Centre Européen d'étude du diabète)

> CeeD (Centre Européen d'étude du diabète) is a VC fund backing Diabetes and Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Strassbourg, France
- Total investments: 1
- Last investment: Oct 2015
- Lead investor: 0%
- Last updated: Aug 2026

CeeD (Centre Européen d'étude du diabète) is a VC fund in Strassbourg focused on Diabetes and Health Care. le Centre Européen d’étude du Diabète (CeeD) est une structure de recherche translationnelle, qui associe médecins et chercheurs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Diabetes | 1 | 100% |
| Health Care | 1 | 100% |
| Medical Device | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Defymed | Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a preciseadministration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were developed by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device (in clinics). Defymed owns an exclusive technology and know-how which positions its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer management. Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey. | $2.7M | Seed | Oct 27, 2015 |  |

1 of 1 investments shown.

## Co-investors
- [Cap Innov'Est](https://shizune.co/investors/profile/cap-innovest) — VC Fund, 1 deal together
- CTTM — VC Fund, 1 deal together
- [Emertec](https://shizune.co/investors/profile/emertec-gestion) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does CeeD (Centre Européen d'étude du diabète) invest in?

CeeD (Centre Européen d'étude du diabète) invests primarily in Diabetes, Health Care and Medical Device startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did CeeD (Centre Européen d'étude du diabète) last invest?

The most recent investment recorded for CeeD (Centre Européen d'étude du diabète) closed in Oct 2015. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co